{
    "nctId": "NCT00885755",
    "briefTitle": "A Study of Herceptin (Trastuzumab)and Biomarkers in Patients With HER2-Positive Metastatic Breast Cancer",
    "officialTitle": "A Prospective Study to Evaluate Alterations in Molecular Biomarkers in HER2 Neu Positive Metastatic Breast Cancer Together With Assessment of Trastuzumab Use Beyond Progression After Initial Response to Trastuzumab-taxane Based Treatment",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 33,
    "primaryOutcomeMeasure": "Part I: Progression Free Survival (PFS) by Biomarker",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* female patients, \\>=18 years of age;\n* HER2-positive breast cancer;\n* al least one metastatic site amenable for core biopsy;\n* left ventricular ejection fraction \\>50%.\n\nExclusion Criteria:\n\n* prior adjuvant/neoadjuvant Herceptin within past 6 months;\n* prior adjuvant taxane therapy within past 12 months;\n* use of chemotherapy, immunotherapy or biological anticancer therapy within past 3 weeks;\n* known bleeding diatheses.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}